Arcus Biosciences
RCUS
24.52
+0.24
+0.99%
Arcus Biosciences
US · RCUS
#2467 by market cap
Listed 2018
24.52
+0.24
+0.99%
Live - 5344 symbols - heartbeat 181s ago
· 2026-10-07 19:54
After-hours
24.52
0.00%
- Market cap
- 3.12B
- P/E (TTM)i
- -6.22
- P/Bi
- 6.73
- EPSi
- -3.29
- Div yieldi
- 0.00%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on RCUS?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
42.13 +71.8%
Price target rangecurrent 24.52
Low29.00
Avg42.13
High47.00
Buy 89%
Hold 11%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | BofA Securities | -- | HOLD | 29.00 |
| 2026-10-03 | LifeSci Capital | -- | BUY | 46.00 |
| 2026-09-30 | Wedbush | -- | BUY | 43.00 |
| 2026-09-27 | LifeSci Capital | -- | BUY | 46.00 |
| 2026-09-25 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-09-24 | LifeSci Capital | -- | BUY | 46.00 |
| 2026-09-16 | TD Cowen | -- | BUY | -- |
| 2026-09-13 | LifeSci Capital | -- | BUY | 46.00 |
| 2026-09-09 | Citi | -- | BUY | 45.00 |
| 2026-09-08 | Truist Financial | -- | BUY | 40.00 |
| 2026-08-11 | BofA Securities | -- | HOLD | 29.00 |
| 2026-08-10 | Goldman Sachs | -- | BUY | 42.00 |
| 2026-08-07 | Goldman Sachs | -- | BUY | 42.00 |
| 2026-08-06 | Truist Financial | -- | BUY | -- |
| 2026-08-06 | Wedbush | -- | BUY | 43.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-08-05 | LifeSci Capital | -- | BUY | 46.00 |
| 2026-08-05 | Mizuho Securities | -- | BUY | 47.00 |
| 2026-08-03 | BofA Securities | -- | HOLD | 29.00 |
| 2026-07-23 | Truist Financial | -- | BUY | -- |
| 2026-07-23 | Wedbush | -- | BUY | 41.00 |
| 2026-07-23 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-07-22 | Citi | -- | BUY | 45.00 |
| 2026-07-20 | LifeSci Capital | -- | BUY | 46.00 |
| 2026-07-20 | H.C. Wainwright | -- | BUY | 45.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Wells Fargo moved from Buy to Hold on 2026-02-12.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-02-12 | Wells Fargo | BUY → HOLD | 23.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | After close | ±13.29% | +2.27% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±17.69% | -0.23% (in line) |
| 2025/Q4 | 2026-02-25 | After close | ±24.27% | -3.60% (in line) |
| 2025/Q2 | 2025-08-06 | After close | ±28.40% | -2.21% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±15.39% | -1.35% (in line) |
| 2024/Q4 | 2025-02-25 | After close | ±14.65% | -0.98% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±23.17% | +4.64% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±17.90% | +14.02% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±12.29% | +5.83% (in line) |
| 2023/Q4 | 2024-02-21 | After close | ±17.65% | +19.87% (beat) |
| 2023/Q3 | 2023-11-07 | After close | ±17.43% | -2.67% (in line) |
| 2023/Q2 | 2023-08-07 | -- | ±15.38% | -4.26% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.